Crossfiled1 outlets · filed 25 October 2026
Seeking Value: GSK’s Drug-Safety AI Strategy Connects Data With Outcomes
This story is from the archive. It was covered between
25 October 2026 and
25 October 2026, and nothing
below has been updated since. See what is happening now.
GSK and Cognizant aim to cut delays in drug-safety reviews, improve traceability and leave medical decisions to specialists.
How it broke
Newsweek
Get the 5 stories every outlet is covering, every morning. Free.
One email a day. Unsubscribe in one click. We host no journalism and never sell your address.
More on Tech & AI
- Elon Musk Says Ukraine Violated Starlink’s Rules 10 outlets
- Zuckerberg wins Meta deal to help him foot bill for possible California billionaire tax 4 outlets
- 9 Unique Apps to Try on the iPhone Duo 3 outlets
- AI delivers ‘zero financial payoff’ to most companies, Apollo economist says 2 outlets
- Ray-Ban Meta Audio AI Glasses Cost More While Ditching a Key Feature: Review 2 outlets
- The ‘Exotic Physics’ Behind a Mysterious 1,000-Mile Cloud on Mars 2 outlets